Fragile histidine triad (fhit) compositions and uses thereof

Abstract

Provided herein are methods and compositions for the diagnosis, prognosis and treatment of a cancer associated disorders using the Fhit gene.

What is claimed is: 
     
         1 . A pharmaceutical composition for treating a cancer associated disorder, comprising at least one isolated Fhit gene product, and a pharmaceutically-acceptable carrier. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the Fhit gene product comprises Fhit-His6. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the Fhit-His6, comprises an adenovirus carrying a FHIT-His6 cDNA. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the Fhit gene product comprises a recombinant adenovirus carrying fragile histidine triad (Fhit) FHIT cDNA modified at its 3′ with a sequence encoding a histidine-six epitope tag (AdFHIT-His6). 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the amount of Fhit gene product is administered in an amount sufficient to mediate an apoptotic process in the cell. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the amount of Fhit gene product is administered in an amount sufficient to cause generation of reactive oxygen species (ROS) in the cell. 
     
     
         7 . The pharmaceutical composition of  claim 1 , further comprising at least one chemotherapeutic composition present in a dosage form that contacts at least one cell at a time subsequent to the at least one isolated Fhit gene product. 
     
     
         8 . The pharmaceutical composition of  claim 7 , wherein the chemotherapeutic composition comprises one or more of: paclitaxel or cisplatin. 
     
     
         9 . The pharmaceutical composition of  claim 8 , the paclitaxel is present in an amount between about 50 ng/ml to about 500 ng/ml. 
     
     
         10 . The pharmaceutical composition of  claim 8 , the paclitaxel is present in an amount of: 50 ng/ml, 100 ng/ml, or 500 ng/ml. 
     
     
         11 . The pharmaceutical composition of  claim 13 , wherein the cisplatin is present in an amount between about 0.05 mM to about 0.2 mM. 
     
     
         12 . The pharmaceutical composition of  claim 8 , the cisplatin is present in an amount of: 0.05 mM, 0.1 mM, or 0.2 mM. 
     
     
         13 . The pharmaceutical composition of  claim 8 , wherein the cancer comprises one or more of: a lung cancer, a colon cancer, or a gastric cancer.